Drug intelligence / Profile preview

chlorpheniramine + dextromethorphan + phenylephrine (Alliant Pharmaceuticals)

Development stage
Unknown
Lead developer
Sciele Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Rondec DM is an oral combination medication containing chlorpheniramine maleate, dextromethorphan hydrobromide, and phenylephrine hydrochloride. It is indicated for the symptomatic relief of cough, nasal congestion, and allergic symptoms associated with the common cold, influenza, hay fever, or other upper respiratory allergies such as sinusitis and bronchitis. Chlorpheniramine is a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells. Dextromethorphan is an antitussive agent that acts centrally on the cough center in the medulla, primarily through sigma-1 receptor agonism and NMDA receptor antagonism. Phenylephrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-1 adrenergic receptors, leading to vasoconstriction in the nasal mucosa and reducing sinus pressure. The drug was developed and manufactured by Alliant Pharmaceuticals and is typically available in syrup or drop formulations.

Brand names
Rondec DM
02

Targets

HRH1 (Histamine H1 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)Nicotinic Acetylcholine ReceptorADRA1A (α1A)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on chlorpheniramine + dextromethorphan + phenylephrine (Alliant Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorpheniramine + dextromethorphan + phenylephrine (Alliant Pharmaceuticals).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call